RESUMO
Background: There is limited published data regarding the distribution of esophageal cancer patients by sub-regions, districts and ethnicity in Uganda. Objectives: To study the distribution by sub-regions, districts, ethnicity and sub-regions post-care outcomes of esophageal cancer patients in care over ten years at the Uganda Cancer Institute. Methods: Patients' charts with confirmed diagnoses of esophageal cancer for 2009-2019 were identified. Case information, which included demographics, clinical presentation, distribution by sub-regions, districts, ethnicity and sub-regions post-care outcomes, were retrospectively abstracted. Results: Central 671(34.15%), Southwestern 308(15.67%), Elgon 176(8.95%) and East central 163(8.29%) sub-regions had most patients. Mostly from administrative districts of Wakiso 167(8.50%), Mbarara 51(2.59%), Tororo 53(2.70%), Busia 33(1.68). Baganda, Banyakole, Bagisu and Basoga ethnic groups predominate. Patients from neighbouring countries were mainly from Rwanda 56(2.85%), South Sudan 24(1.22%), then Kenya 21(1.07%), and Rwandese, Dinka and Luo by ethnicity, respectively. Central and Southwestern sub-regions had the most post-care outcomes of the patients regarding living, death, and loss to follow-up. Conclusion: Patients are commonly from the administrative districts of Central, Southwestern, Elgon and East Central sub-regions and neighbouring countries of Rwanda, South Sudan and Kenya. Baganda, Banyakole, Bagisu and Basoga are the main ethnic groups. Central and Southwestern sub-regions are with most post-care outcomes.
Assuntos
Neoplasias Esofágicas , Etnicidade , Humanos , Neoplasias Esofágicas/etnologia , Neoplasias Esofágicas/terapia , Uganda/epidemiologia , Masculino , Feminino , Pessoa de Meia-Idade , Estudos Retrospectivos , Idoso , Etnicidade/estatística & dados numéricos , AdultoRESUMO
BACKGROUND: Despite Asian Americans having a heightened risk profile for esophageal cancer, racial disparities within this group have not been investigated. This study seeks to evaluate the 30-day postoperative outcomes for Asian Americans following esophagectomy. METHODS: A retrospective analysis was performed using ACS-NSQIP esophagectomy targeted database 2016-2021. A 1:3 propensity-score matching was applied to Asian Americans and Caucasians who underwent esophagectomy to compare their 30-day outcomes. RESULTS: There were 229 Asian Americans and 5303 Caucasians identified. Asian Americans were more likely to have squamous cell carcinoma than adenocarcinoma. After matching, 687 Caucasians were included. Asian Americans had higher pulmonary complications (22.27 â% vs 16.01 â%, p â= â0.04) especially pneumonia (16.59 â% vs 11.06 â%, p â= â0.04), renal dysfunction (2.62 â% vs 0.44 â%, p â= â0.01) especially progressive renal insufficiency (1.31 â% vs 0.15 â%, p â< â0.05), and bleeding events (18.34 â% vs 9.02 â%, p â< â0.01). In addition, Asian Americans had longer LOS (11.83 â± â9.39 vs 10.23 â± â7.34 days, p â= â0.03). CONCLUSION: Asian Americans were found to face higher 30-day surgical complications following esophagectomy. Continued investigation into the underlying causes and potential mitigation strategies for these disparities are needed.
Assuntos
Asiático , Neoplasias Esofágicas , Esofagectomia , Complicações Pós-Operatórias , Pontuação de Propensão , Humanos , Esofagectomia/efeitos adversos , Masculino , Feminino , Complicações Pós-Operatórias/etnologia , Complicações Pós-Operatórias/epidemiologia , Pessoa de Meia-Idade , Estudos Retrospectivos , Asiático/estatística & dados numéricos , Neoplasias Esofágicas/cirurgia , Neoplasias Esofágicas/etnologia , Idoso , Bases de Dados Factuais , Estados Unidos/epidemiologia , População Branca/estatística & dados numéricos , Adenocarcinoma/cirurgia , Adenocarcinoma/etnologiaRESUMO
BACKGROUND: Hispanics are the fastest-growing minority and the second largest ethnic group in the United States, accounting for 18% of the national population. The American Cancer Society estimated 18,440 new cases of esophageal cancer (EC) in the United States in 2020. Hispanics are reported to be at high risk of EC. We sought to interrogate the demographic patterns of EC in Hispanics. Secondary objective was to examine evidence of socioeconomic disparities and differential therapy. METHODS: We identified Hispanic vs non-Hispanic patients with EC in the National Cancer Database between 2005 and 2015. Groups were statistically equated through propensity score-matched analysis. RESULTS: A total of 3205 Hispanics (3.8%) were identified among 85,004 patients with EC. We identified significant disparities between Hispanic and non-Hispanic groups. Disparities among Hispanics included higher prevalence of squamous EC, higher likelihood of stage IV cancer diagnosis, younger age, uninsured status, and income< $38,000. Hispanics were less likely to have surgical intervention or any type of treatment when compared to non-Hispanics. Multivariate analysis showed that age, ethnicity, treatment, histology, grade, stage, and Charlson-Deyo scores were independent predictors of survival. Treated Hispanics survived longer than non-Hispanics. CONCLUSION: Despite the lower prevalence of EC, there is a disproportionately higher prevalence of metastatic and untreated cases among Hispanics. This disparity may be explained by Hispanics' limited access to medical care, exacerbated by their socioeconomic and insurance status. Further study is warranted to examine these health disparities among Hispanics.
Assuntos
Bases de Dados Factuais , Neoplasias Esofágicas , Disparidades em Assistência à Saúde , Hispânico ou Latino , Humanos , Hispânico ou Latino/estatística & dados numéricos , Neoplasias Esofágicas/etnologia , Neoplasias Esofágicas/epidemiologia , Neoplasias Esofágicas/terapia , Neoplasias Esofágicas/patologia , Masculino , Feminino , Pessoa de Meia-Idade , Estados Unidos/epidemiologia , Idoso , Disparidades em Assistência à Saúde/estatística & dados numéricos , Disparidades em Assistência à Saúde/etnologia , Estadiamento de Neoplasias , Fatores Etários , Pessoas sem Cobertura de Seguro de Saúde/estatística & dados numéricos , Fatores Socioeconômicos , Carcinoma de Células Escamosas/etnologia , Carcinoma de Células Escamosas/terapia , Carcinoma de Células Escamosas/epidemiologia , Carcinoma de Células Escamosas/patologia , Pontuação de Propensão , Renda/estatística & dados numéricos , Adulto , Adenocarcinoma/etnologia , Adenocarcinoma/terapia , Adenocarcinoma/patologiaRESUMO
Objective Recently, numerous studies have yielded inconsistent results regarding the effect of metformin on esophageal cancer risk in type 2 diabetes mellitus patients. The purpose of this study is to systematically assess this effect using meta-analysis. Methods We searched clinical studies on metformin and esophageal cancer risk in PubMed, Embase, and the Cochrane Library. After literature screening, a series of meta-analyses were conducted using RevMan 5.3 software. The pooled hazard ratio (HR) and the corresponding 95% confidence interval (CI) were used as the effect size. Results Five eligible studies (four cohort studies and one casecontrol study) were included for our meta-analysis using a random-effect model. The analysis showed that metformin could not reduce esophageal cancer risk in type 2 diabetes mellitus patients (HR 0.88, 95% CI 0.601.28, P > 0.05). Subgroup analyses by geographic location showed that metformin significantly reduced esophageal cancer risk in Asian patients with type 2 diabetes mellitus (HR 0.59, 95% CI 0.390.91, P = 0.02), without heterogeneity between studies (P = 0.80 and I2 = 0%). Conclusions Overall, our systematic review and meta-analysis demonstrate that metformin does not reduce esophageal cancer risk in type 2 diabetes mellitus patients. However, a significant reduction in esophageal cancer risk in Asian populations remains to be clarified (AU)